Merck Canada Inc.

Merck Sharp + Dohme Corp.

Julie Farand

Yongxin Han

Jason Burch

Claudio F Sturino

Michel L Belley

Claude Dufresne

John Colucci

Carl Berthelette

Michael Boyd

Mario Girard

The invention is directed to &#x3b2;-carboline sulphonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, inflammation, osteoarthritis, and rheumatoid arthritis. Pharmaceutical compositions and methods of use are also included.

Beta carboline sulphonylurea derivatives as EP4 receptor antagonists

The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I): wherein A and B represents either a nitrogen atom or a CH group with the proviso that they cannot both simultaneously be CH, Q can represent a nitrogen or a carbon atom, and Y and Z are either a nitrogen atom, a N(O) group or a C(R) group. Pharmaceutical compositions comprising the derivatives of formula (I) are also included. 

Quinoline derivatives as EP4 antagonists

The invention is directed to naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.

Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists

Growing community of inventors

Jersey City, NJ, United States of America

Julie Farand